What is the bacterial coverage of Unasyn (Ampicillin-Sulbactam)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 28, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Bacterial Coverage of Unasyn (Ampicillin-Sulbactam)

Unasyn (ampicillin-sulbactam) provides broad-spectrum coverage against gram-positive, gram-negative, and anaerobic bacteria, including beta-lactamase producing organisms. The combination effectively extends ampicillin's spectrum by adding sulbactam, which irreversibly inhibits many clinically important beta-lactamases.

Spectrum of Activity

Gram-Positive Bacteria

  • Staphylococcus species (including beta-lactamase producing strains)
    • Staphylococcus aureus (methicillin-susceptible)
    • Staphylococcus saprophyticus
  • Streptococcus species
    • Streptococcus pneumoniae
    • Streptococcus pyogenes
    • Streptococcus viridans group
  • Enterococcus faecalis

Gram-Negative Bacteria

  • Haemophilus influenzae (beta-lactamase and non-beta-lactamase producing)
  • Moraxella catarrhalis (formerly Branhamella catarrhalis)
  • Escherichia coli (beta-lactamase and non-beta-lactamase producing)
  • Klebsiella species
  • Proteus species (mirabilis and vulgaris)
  • Providencia species (rettgeri and stuartii)
  • Morganella morganii
  • Neisseria gonorrhoeae
  • Acinetobacter species

Anaerobic Bacteria

  • Bacteroides species, including Bacteroides fragilis
  • Clostridium species
  • Peptococcus species
  • Peptostreptococcus species

Clinical Applications

Unasyn is particularly valuable in treating:

  1. Mixed infections where both aerobic and anaerobic coverage is needed 1
  2. Intra-abdominal infections 2
  3. Skin and soft tissue infections, particularly animal and human bites 2
  4. Gynecological infections including PID 2
  5. Urogenital tract infections 3, 4

Important Considerations

  • Unasyn does not cover MRSA, Pseudomonas aeruginosa, or extended-spectrum beta-lactamase (ESBL) producing organisms
  • For serious infections, the typical dosage is 3g IV every 6 hours 2
  • When treating polymicrobial infections, Unasyn provides better anaerobic coverage than cephalosporins alone 2
  • For animal and human bites, Unasyn is specifically recommended for intravenous treatment 2

Advantages Over Other Agents

Ampicillin-sulbactam has several advantages over using metronidazole plus another agent:

  1. It provides single-agent coverage for mixed infections
  2. Unlike metronidazole, which requires combination with agents effective against gram-positive cocci 5, Unasyn inherently covers both gram-positive and anaerobic organisms
  3. It demonstrates bactericidal activity against a wide range of pathogens 6

Limitations

  • Not effective against ESBL-producing organisms
  • Limited activity against Pseudomonas species
  • Not effective against MRSA
  • Pain at injection site is a common adverse effect with intramuscular administration 4

For empiric treatment of polymicrobial infections, Unasyn provides excellent broad-spectrum coverage and is particularly valuable when both aerobic and anaerobic pathogens are suspected.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

[The use of ampicillin/sulbactam (Unasyn) in treating inflammatory urological diseases].

Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic], 1991

Guideline

Antimicrobial Spectrum of Metronidazole

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.